157 related articles for article (PubMed ID: 36266779)
21. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
22. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy and safety of ruxolitinib in patients with myelofibrosis: a single-center retrospective analysis].
Edahiro Y; Komatsu N
Rinsho Ketsueki; 2019; 60(7):755-760. PubMed ID: 31391362
[TBL] [Abstract][Full Text] [Related]
24. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Jourdan E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Shen J; Berry T; Brownstein C; Mesa RA
Am J Hematol; 2020 Jun; 95(6):594-603. PubMed ID: 32129512
[TBL] [Abstract][Full Text] [Related]
25. Low-dose ruxolitinib shows effective in treating myelofibrosis.
Yang Y; Luo H; Zheng Y; Zou Z; Niu T; Jia Y; Zhu H; Liu T; Wu Y; Chang H; Ji J; Li J; Pan L
Ann Hematol; 2021 Jan; 100(1):135-141. PubMed ID: 33083863
[TBL] [Abstract][Full Text] [Related]
26. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.
Wade R; Rose M; Neilson AR; Stirk L; Rodriguez-Lopez R; Bowen D; Craig D; Woolacott N
Pharmacoeconomics; 2013 Oct; 31(10):841-52. PubMed ID: 23996108
[TBL] [Abstract][Full Text] [Related]
27. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
[TBL] [Abstract][Full Text] [Related]
28. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Sun W; Sandor V; Kantarjian HM
Br J Haematol; 2013 May; 161(4):508-16. PubMed ID: 23480528
[TBL] [Abstract][Full Text] [Related]
29. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
Gerds AT; Yu J; Scherber RM; Paranagama D; Kish JK; Visaria J; Singhal M; Verstovsek S; Pemmaraju N
Acta Haematol; 2022; 145(4):448-453. PubMed ID: 35008087
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey.
Soyer N; Ali R; Turgut M; Haznedaroğlu İC; Yılmaz F; Aydoğdu İ; Pir A; Karakuş V; Özgür G; Kiş C; Ceran F; İlhan G; Özkan M; Aslaner M; İnce İ; Yavaşoğlu İ; Gediz F; Sönmez M; Güvenç B; Özet G; Kaya E; Vural F; Şahin F; Töbü M; Durusoy R; Saydam G
Turk J Med Sci; 2021 Jun; 51(3):1033-1042. PubMed ID: 33315343
[TBL] [Abstract][Full Text] [Related]
31. Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology.
Jung EH; Hong J; Kim SY; Park Y; Yuh YJ; Mun YC; Lee WS; Park SK; Bang SM
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e931-e937. PubMed ID: 35858905
[TBL] [Abstract][Full Text] [Related]
32. Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib.
Iurlo A; Galli N; Bucelli C; Artuso S; Consonni D; Cattaneo D
Br J Haematol; 2023 Mar; 200(6):e53-e55. PubMed ID: 36600586
[No Abstract] [Full Text] [Related]
33. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
[TBL] [Abstract][Full Text] [Related]
34. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.
Maffioli M; Mora B; Ball S; Iurlo A; Elli EM; Finazzi MC; Polverelli N; Rumi E; Caramella M; Carraro MC; D'Adda M; Molteni A; Sissa C; Lunghi F; Vismara A; Ubezio M; Guidetti A; Caberlon S; Anghilieri M; Komrokji R; Cattaneo D; Della Porta MG; Giorgino T; Bertù L; Brociner M; Kuykendall A; Passamonti F
Blood Adv; 2022 Mar; 6(6):1855-1864. PubMed ID: 35130339
[TBL] [Abstract][Full Text] [Related]
35. Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study.
Qu S; Xu Z; Qin T; Li B; Pan L; Chen J; Yan X; Wu J; Zhang Y; Zhang P; Gale RP; Xiao Z
Hematol Oncol; 2022 Oct; 40(4):787-795. PubMed ID: 35609279
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy and safety of JAK inhibitor ruxolitinib in Chinese patients with myelofibrosis: results of a 1-year follow-up of A2202].
Jin J; Du X; Zhou DB; Li JM; Li JY; Hou M; Liu T; Wu DP; Hu Y; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):858-863. PubMed ID: 27801315
[TBL] [Abstract][Full Text] [Related]
37. Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Palandri F; Bartoletti D; Iurlo A; Bonifacio M; Abruzzese E; Caocci G; Elli EM; Auteri G; Tiribelli M; Polverelli N; Miglino M; Heidel FH; Tieghi A; Benevolo G; Beggiato E; Fava C; Cavazzini F; Pugliese N; Binotto G; Bosi C; Martino B; Crugnola M; Ottaviani E; Micucci G; Trawinska MM; Cuneo A; Bocchia M; Krampera M; Pane F; Lemoli RM; Cilloni D; Vianelli N; Cavo M; Palumbo GA; Breccia M
Cancer; 2022 Jul; 128(13):2449-2454. PubMed ID: 35363892
[TBL] [Abstract][Full Text] [Related]
38. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Mead AJ; Milojkovic D; Knapper S; Garg M; Chacko J; Farquharson M; Yin J; Ali S; Clark RE; Andrews C; Dawson MK; Harrison C
Br J Haematol; 2015 Jul; 170(1):29-39. PubMed ID: 25824940
[TBL] [Abstract][Full Text] [Related]
39. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
Duan M; Zhou D
Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
[No Abstract] [Full Text] [Related]
40. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.
Barosi G; Viarengo G; Pecci A; Rosti V; Piaggio G; Marchetti M; Frassoni F
Blood; 2001 Dec; 98(12):3249-55. PubMed ID: 11719361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
